Zura Bio Shares Plunge After Phase 2 Hidradenitis Suppurativa Trial Misses Endpoints
Zura Bio shares plunged after its Phase 2 TibuSHIELD trial of tibulizumab in hidradenitis suppurativa failed to meet primary and key secondary endpoints.
/ 3 items
#ZURA↓
William Blair Initiates Outperform Coverage on Zura Bio, Citing Strong Potential for Tibulizumab
William Blair cites strong upside potential for lead candidate tibulizumab in hidradenitis suppurativa and systemic sclerosis.
Wedbush Starts Coverage on Zura Bio with Positive Outlook
Wedbush gives Zura Bio an Outperform rating and $15 target, highlighting upcoming clinical catalysts and potential stock growth through 2026.